<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

<u>Materials</u>

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	res (muicate where provided.	n/a. Antibodies were not used in
,		this study
Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide		n/a. Cell lines
accession number in repository OR supplier name, catalog number, clone number, OR RRID		were not used in this study.
Primary cultures: Provide species, strain, sex of origin,		n/a. Primary
genetic modification status.		cultures were no involved.
Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic	res (maicate where provided.	n/a. Laboratory
modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		animals were not used in this study
Animal observed in or captured from the field: Provide		n/a. Animal
species, sex and age where possible		observed in or
		captured from th
		field was not
		involved in this study.
Model organisms: Provide Accession number in		n/a. Model
repository (where relevant) OR RRID		organisms were
		not used in this study.
Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if		n/a. Plants were
available, and source (including location for collected wild specimens)		not used in this study.
Microbes: provide species and strain, unique accession		n/a. Microbes
number if available, and source		were not used in this study.
Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent		n/a. No human
committee(s), provide reference number for approval.		participants were involved in this study.
Provide statement confirming informed consent obtained from		n/a. No human
study participants.		participants were
		involved in this
		study.
Report on age and sex for all study participants.		n/a. No human
		participants were
		involved in this
		study

study.

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.		n/a. This is not a clinical trial.
Laboratory protocol Provide DOI or other citation details if detailed step-by- step protocols are available.	Yes (indicate where provided:	n/a n/a. Laboratory protocol is not available for this study.
Experimental study design (statistics details) State whether and how the following have been done, or if they were not carried out.	Yes (indicate where provided:	n/a
Sample size determination	Yes. In Page 7, Line 98-11, section 2.1/paragraph 1; and in Page 8-9, Line 125-126, section 2.2/paragraph 1.	
Randomisation		n/a. Randomisation was not used in this study.
Blinding		n/a. Blinding was not used in this study.
Inclusion/exclusion criteria	Yes. In Page 7, Line 96-98, section 2.1/paragraph 1; In Page 8, Line 106-111, section 2.1/paragraph 2; and in Page 8-9, Line 125-127, section 2.2/paragraph 1.	
Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory	res (mareate where provided.	n/a
Define whether data describe technical or biological replicates		n/a
Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	,	n/a. Human participants were not involved in this study.
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a. Experimental animals were not involved in this study.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		n/a. Specimen and field samples were not involved in this study.
Dual Use Research of Concern (DURC) If study is subject to dual use research of concern, state the authority granting approval and reference number for	Yes (indicate where provided:	n/a n/a. This study is not subject to
the regulatory approval		dual use research of concern.

<u>Analysis</u>

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and	Yes.	
whether the criteria for exclusion were determined and	In Page 7-8, Line 106-111, section	
specified in advance.	2.1/paragraph 2.	

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	Yes.	
	In Page 10, Line 151-153, section 2.4/paragraph 1.	

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		n/a.
If data are publicly available, provide accession number in repository or DOI or URL.	Yes. In Page 7, Line 95-96, section 2.1/paragraph 1; and in Page 8, Line 124-125, section 2.2/paragraph 1.	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		n/a. Publicly available data are not reused.

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	Yes. In Page 8, Line 111-112, section 2.1/paragraph 2; In Page 8, Line 118-119, section 2.1/paragraph 3; In Page 9, Line 138-139, section 2.2/paragraph 1; in Page 9, Line 143-146, section 2.3/paragraph 1; and in Page 10, Line 150-151, section 2.4/paragraph 1.	
If code is publicly available, provide accession number in repository, or DOI or URL.		n/a. Code is not publicly available.

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/atm-20-5989	
7 truck information. http://dx.doi.org/10.2103//atin-20-3/0/	